$CLDX TSP Capital Management Group LLC Increases Position in Celldex Therapeutics, Inc. (CLDX)
Posted by Reagan on Mar 31st, 2016 // No Comments
Celldex Therapeutics logoTSP Capital Management Group LLC boosted its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 0.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 831,648 shares of the biopharmaceutical company’s stock after buying an additional 6,967 shares during the period. Celldex Therapeutics comprises approximately 7.0% of TSP Capital Management Group LLC’s holdings, making the stock its largest position. TSP Capital Management Group LLC owned approximately 0.84% of Celldex Therapeutics worth $13,040,000 as of its most recent filing with the SEC.
Other hedge funds have also recently bought and sold shares of the company. Bedell Frazier Investment Counseling LLC raised its stake in Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares in the last quarter. Columbia Wanger Asset Management LLC raised its stake in Celldex Therapeutics by 16.1% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 3,610,008 shares of the biopharmaceutical company’s stock worth $56,605,000 after buying an additional 500,393 shares in the last quarter. ProShare Advisors LLC raised its stake in Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock worth $1,469,000 after buying an additional 9,072 shares in the last quarter. Columbus Circle Investors raised its stake in Celldex Therapeutics by 10.5% in the fourth quarter. Columbus Circle Investors now owns 655,739 shares of the biopharmaceutical company’s stock worth $10,282,000 after buying an additional 62,246 shares in the last quarter. Finally, Suffolk Capital Management LLC raised its stake in Celldex Therapeutics by 32.4% in the fourth quarter. Suffolk Capital Management LLC now owns 167,215 shares of the biopharmaceutical company’s stock worth $2,622,000 after buying an additional 40,906 shares in the last quarter.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) opened at 3.60 on Thursday. The company has a 50-day moving average price of $5.40 and a 200-day moving average price of $11.39. The firm’s market cap is $355.33 million. Celldex Therapeutics, Inc. has a 12-month low of $2.96 and a 12-month high of $30.28.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.02. The firm earned $1.80 million during the quarter, compared to analyst estimates of $0.80 million. During the same quarter in the previous year, the business earned ($0.36) earnings per share. Celldex Therapeutics’s revenue for the quarter was up 21.1% compared to the same quarter last year. On average, analysts predict that Celldex Therapeutics, Inc. will post ($1.33) earnings per share for the current year.
A number of analysts have commented on the stock. Roth Capital reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, March 8th. Brean Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, March 8th. Leerink Partner lowered shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, March 7th. HC Wainwright reduced their price objective on shares of Celldex Therapeutics from $25.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, March 8th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $12.00 price objective (down from $28.00) on shares of Celldex Therapeutics in a research note on Tuesday, March 8th. Seven research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newslette
Posted by Reagan on Mar 31st, 2016 // No Comments
Celldex Therapeutics logoTSP Capital Management Group LLC boosted its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 0.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 831,648 shares of the biopharmaceutical company’s stock after buying an additional 6,967 shares during the period. Celldex Therapeutics comprises approximately 7.0% of TSP Capital Management Group LLC’s holdings, making the stock its largest position. TSP Capital Management Group LLC owned approximately 0.84% of Celldex Therapeutics worth $13,040,000 as of its most recent filing with the SEC.
Other hedge funds have also recently bought and sold shares of the company. Bedell Frazier Investment Counseling LLC raised its stake in Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares in the last quarter. Columbia Wanger Asset Management LLC raised its stake in Celldex Therapeutics by 16.1% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 3,610,008 shares of the biopharmaceutical company’s stock worth $56,605,000 after buying an additional 500,393 shares in the last quarter. ProShare Advisors LLC raised its stake in Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock worth $1,469,000 after buying an additional 9,072 shares in the last quarter. Columbus Circle Investors raised its stake in Celldex Therapeutics by 10.5% in the fourth quarter. Columbus Circle Investors now owns 655,739 shares of the biopharmaceutical company’s stock worth $10,282,000 after buying an additional 62,246 shares in the last quarter. Finally, Suffolk Capital Management LLC raised its stake in Celldex Therapeutics by 32.4% in the fourth quarter. Suffolk Capital Management LLC now owns 167,215 shares of the biopharmaceutical company’s stock worth $2,622,000 after buying an additional 40,906 shares in the last quarter.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) opened at 3.60 on Thursday. The company has a 50-day moving average price of $5.40 and a 200-day moving average price of $11.39. The firm’s market cap is $355.33 million. Celldex Therapeutics, Inc. has a 12-month low of $2.96 and a 12-month high of $30.28.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.02. The firm earned $1.80 million during the quarter, compared to analyst estimates of $0.80 million. During the same quarter in the previous year, the business earned ($0.36) earnings per share. Celldex Therapeutics’s revenue for the quarter was up 21.1% compared to the same quarter last year. On average, analysts predict that Celldex Therapeutics, Inc. will post ($1.33) earnings per share for the current year.
A number of analysts have commented on the stock. Roth Capital reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, March 8th. Brean Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, March 8th. Leerink Partner lowered shares of Celldex Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, March 7th. HC Wainwright reduced their price objective on shares of Celldex Therapeutics from $25.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, March 8th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $12.00 price objective (down from $28.00) on shares of Celldex Therapeutics in a research note on Tuesday, March 8th. Seven research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newslette
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
